Table 1:

Summary of cost-effectiveness analysis for the base case

StrategyCost, $ (95%CI)*Effectiveness, QALY (95%CI)ICER, $/QALY
Clopidogrel39 601 (8 343–111 186)7.41 (1.05–14.79)
Prasugrel40 422 (9 002–112 574)7.43 (1.06–14.79)57 630
Ticagrelor40 649 (9 327–111 881)7.50 (1.12–14.84)12 205
  • Note: CI = confidence interval, ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life-year.

  • * All costs are in 2012 Canadian dollars.

  • Compared with common reference of clopidogrel.

  • Extendedly dominated (ICER is higher than that of a more effective strategy).